Patents by Inventor Martha Susan Hayden-Ledbetter

Martha Susan Hayden-Ledbetter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190290755
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition; the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 26, 2019
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Patent number: 10143748
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 4, 2018
    Assignee: Aptevo Research and Development LLC
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20180118823
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: June 8, 2017
    Publication date: May 3, 2018
    Applicant: APTEVO RESEARCH AND DEVELOPMENT LLC
    Inventors: Peter Armstrong THOMPSON, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Laura Sue GROSMAIRE, Robert BADER, William BRADY
  • Publication number: 20140154250
    Abstract: The present disclosure relates to single-chain multivalent binding proteins, compositions comprising the single-chain multivalent binding proteins, and methods of making and using the single chain-multivalent binding proteins.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 5, 2014
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
  • Publication number: 20140154252
    Abstract: Variations on the structural themes for multivalent binding molecules with effector function, or scorpions, will be apparent to those of skill in the art upon review of the present disclosure, and such variant structures are within the scope of the invention.
    Type: Application
    Filed: March 15, 2013
    Publication date: June 5, 2014
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, WILLIAM BRADY
  • Publication number: 20140141022
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 22, 2014
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
  • Publication number: 20140127203
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 8, 2014
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: PETER ARMSTRONG THOMPSON, JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, LAURA SUE GROSMAIRE, ROBERT BADER, WILLIAM BRADY
  • Publication number: 20140072562
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: March 15, 2013
    Publication date: March 13, 2014
    Applicant: Emergent Product Development Seattle, LLC
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20140010813
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 9, 2014
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20140004117
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 2, 2014
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20130266561
    Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
    Type: Application
    Filed: March 15, 2013
    Publication date: October 10, 2013
    Inventors: Laura Sue Grosmaire, Martha Susan Hayden-Ledbetter, Jeffrey A. Ledbetter, Peter Armstrong Thompson, Sandy Alexander Simon, William Brady
  • Publication number: 20130195850
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: November 15, 2012
    Publication date: August 1, 2013
    Applicant: EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC
    Inventors: Philip TAN, Sandy Alexander SIMON, Charles G. CERVENY, Christy Anne NILSSON, William BRADY, Jeffrey A. LEDBETTER, Martha Susan HAYDEN-LEDBETTER, Peter Armstrong THOMPSON, Cecile MORALES
  • Patent number: 8409577
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: April 2, 2013
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
  • Patent number: 8197810
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: June 12, 2012
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
  • Patent number: 8188237
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: May 29, 2012
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
  • Patent number: 8147835
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Grant
    Filed: August 13, 2009
    Date of Patent: April 3, 2012
    Assignee: Emergent Product Development Seattle, LLC
    Inventors: Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter
  • Publication number: 20120034245
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: June 12, 2007
    Publication date: February 9, 2012
    Applicant: Emergent Product Development Seattle, LLC
    Inventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
  • Publication number: 20110171208
    Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
    Type: Application
    Filed: April 11, 2009
    Publication date: July 14, 2011
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: Philip Tan, Sandy Alexander Simon, Charles G. Cerveny, Christy Anne Nilsson, William Brady, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Peter Armstrong Thompson, Cecile Morales
  • Publication number: 20110033483
    Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.
    Type: Application
    Filed: June 12, 2007
    Publication date: February 10, 2011
    Applicant: Trubion Pharmaceuticals Inc.
    Inventors: Peter Armstrong Thompson, Jeffrey A. Ledbetter, Martha Susan Hayden-Ledbetter, Laura Sue Grosmaire, Robert Bader, William Brady
  • Publication number: 20100279932
    Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.
    Type: Application
    Filed: July 12, 2010
    Publication date: November 4, 2010
    Applicant: TRUBION PHARMACEUTICALS, INC.
    Inventors: JEFFREY A. LEDBETTER, MARTHA SUSAN HAYDEN-LEDBETTER, PETER AMSTRONG THOMPSON